Sapio Sciences Launches New Molecule Solution Platform
Sapio chemistry solution unifies small-molecule and large-molecule discovery workflows on a single platform.
Sapio Sciences announced the launch of its Sapio chemistry solution, which unifies small-molecule and large-molecule discovery workflows on a single platform. According to the company, the technology enables scientists to draw insights across all their organization’s discovery experiments.
“Many organizations are still running decades-old electronic laboratory notebooks (ELNs) and other software for capturing chemical synthesis experiments and registering small molecules,” said Kevin Cramer, president, CEO, Sapio Sciences. “Large-molecule and small-molecule discovery have traditionally been managed on disparate systems, creating artificial islands that impede scientific collaboration and decision-making. Sapio is excited to give biopharma organizations the opportunity to consolidate all their chemistry experiments on a modern, unified lab platform.”
Reference
Sapio Sciences Unifies Small- and Large-Molecule Discovery on a Single Platform. Business Wire. October 9, 2023. Accessed October 10, 2023. https://www.businesswire.com/news/home/20231009525095/en/Sapio-Sciences-Unifies-Small--and-Large-Molecule-Discovery-on-a-Single-Platform
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
